SAR442085
SAR442085 is an Fc-engineered anti-CD38 monoclonal antibody with a Kd of 0.2 nM for human CD38. SAR442085 inhibits CD38, induces apoptosis, and triggers antibody-dependent cellular cytotoxicity and phagocytosis in CD38-expressing tumor cells. SAR442085 binds allelic variants of FcγRIIa and FcγRIIIa, enhances NK cell activation, degranulation and cytokine secretion, and exerts anti-tumor activity in human Fc receptor transgenic mice. SAR442085 can be used in the research of multiple myeloma.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
-
보관:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
제품 설명
Species Reactivity
Human
In Vitro
SAR442085 potently induces ADCC against RPMI-8226 multiple myeloma cells with an EC50 more than 8-fold lower than Daratumumab (HY-P9915)[1].
SAR442085 inhibits CD38 enzymatic activity[1].
SAR442085 exhibits potent antibody-dependent cellular cytotoxicity (ADCC) and NK cell activation activity against primary myeloma cells and low CD38-density myeloma cells, and enhances CD16 binding to promote natural killer (NK) cell activation and degranulation, thereby killing primary multiple myeloma plasma cells in patient bone marrow aspirates[1][3].
SAR442085 induces potent direct pro-apoptotic activity in SU-DHL-8 lymphoma cells and directly triggers apoptosis in CD38-expressing multiple myeloma cells in vitro[1][2].
SAR442085 (0-100 nM) binds to purified recombinant human CD38 with a Kd of 0.2 nM, demonstrating high affinity for its target antigen[2].
SAR442085 (0-5 μM) binds to purified human FcγRIIIa-158F with a Kp of 119 nM and to FcγRIIIa-158V with a Kp of 46 nM[2].
SAR442085 binds to purified human FcγRIIa-131H with a KD of 720 nM and to FcγRIIa-131R with a KD of 2150 nM, demonstrating specific binding to both activating FcγRIIa variants[2].
SAR442085 (30 minutes at 4°C) binds to CD38+ MOLP-8 MM cells with an apparent Kd of 1.1 nM, showing high target binding affinity[2].
SAR442085 (30 minutes at 4°C) binds with significantly higher apparent affinity and maximal binding to HEK293T cells overexpressing FcγRIIIa-158F, FcγRIIIa-158V, FcγRIIa-131R, or FcγRIIa-131H than Daratumumab (HY-P9915) and Isatuximab (HY-P9976)[2].
SAR442085 (dose range; 30 minutes pre-incubation, 1 hour coculture) induces significantly more potent ADCC against RPMI-8226, MOLP-8, and KMS-12-BM MM cells via NK-92.FcγRIIIa-158F and NK-92.FcγRIIIa-158V effector cells[2].
SAR442085 (dose range; 30 minutes pre-incubation, overnight coculture) induces significantly more potent and efficacious ADCC against RPMI-8226 and KMS-12-BM MM cells via HD PBMC effector cells[2].
SAR442085 (dose range; 30 minutes pre-incubation, overnight coculture) induces significantly more potent ADCC against RPMI-8226 MM cells via purified HD NK effector cells[2].
SAR442085 (dose range; 15 minutes pre-incubation, overnight coculture) induces significantly more potent and efficacious ADCP against RPMI-8226 MM cells via HD monocyte-derived macrophages[2].
SAR442085 (1 hour) inhibits CD38 ecto-enzymatic activity in RPMI-8226 MM cells to a similar extent as Isatuximab (HY-P9976) and significantly more than Daratumumab (HY-P9915)[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
In Vivo
SAR442085 (1.25-10 mg/kg; i.p.; on days 1, 4, 7, 11, 14) provides 90% long-term survival in EL4-huCD38-bearing huFcγR mice at 10 mg/kg, and maintains significant survival benefits at 1.25 mg/kg, outperforming Daratumumab (HY-P9915) and Isatuximab (HY-P9976)[2].
SAR442085 (10 mg/kg; i.p.; 6 injections every 2-3 days; starting at day 7 post-tumor injection) reduces multiple myeloma burden (lower M-spike levels) and improves disease-free survival more effectively than Daratumumab (HY-P9915) and Isatuximab (HY-P9976) in an NK cell-dependent VK*MYC myeloma mouse model[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Human Fc receptor transgenic C57BL/6 (male and female, injected intravenously with 5×105 EL4-huCD38 cells at day 0)[2]
-
Dosage:10 mg/kg; 1.25 mg/kg
-
Administration:i.p.; on days 1, 4, 7, 11, 14
-
Result:Achieved 90% long-term survival (up to 90 days post-tumor implantation) at 10 mg/kg, compared with 50% survival for daratumumab- and isatuximab-treated mice.
Maintained significant survival benefits at 1.25 mg/kg, while daratumumab and isatuximab showed no survival improvement compared with isotype control.
Increased the percentage of splenic NK cells, macrophages, and dendritic cells compared with isotype, isatuximab, or daratumumab treatment.
-
Animal Model:Rag2-/-Il2rg-/- (male and female, sex-matched with NK cell donors, reconstituted with NK cells from human Fc receptor transgenic C57BL/6 mice, injected intravenously with Vk12653-huCD38 cells 1 week post-NK cell reconstitution)[2]
-
Dosage:10 mg/kg
-
Administration:i.p.; 6 injections every 2-3 days; starting at day 7 post-tumor injection
-
Result:Significantly reduced serum M-spike levels compared with isotype control, daratumumab, and isatuximab.
Induced better disease-free survival than daratumumab and isatuximab.
Gene ID
Accession
Target
CD38
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Product Image
신청
ELISA, FACS, Functional assay
Chemical Information
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
보관
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocol
-
Phagocytosis Functional Assay
A phagocytosis functional assay measures the ability of phagocytic cells, such as neutrophils, macrophages, monocytes, or microglia/macrophages, to bind and internalize particulate targets including bacteria, yeast particles, beads, or myelin particles. Fluorescent flow-cytometry assays detect target uptake as fluorescence associated with gated phagocytes, while pH-sensitive dyes such as pHrodo increase signal in acidic phagosomal compartments and therefore preferentially report internalized particles rather than particles remaining outside the cell. Microscopy or high-content imaging can be used to confirm intracellular localization and, in some protocols, to follow uptake kinetics.
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Mammalian live/dead viability and cytotoxicity staining
Live/dead viability and cytotoxicity staining assays are based on the simultaneous detection of intracellular esterase activity in metabolically active (viable) cells and membrane integrity loss in non-viable cells. In commonly used dual-staining approaches, membrane-permeant fluorogenic substrates are converted by intracellular esterases into fluorescent products in live cells, while impermeant DNA-binding dyes selectively enter cells with compromised plasma membranes and label nucleic acids in dead or dying cells, enabling discrimination between viable and non-viable populations by fluorescence microscopy or flow cytometry.
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
순도&문서
References
[2]. Kassem S, et al. SAR442085, a novel anti-CD38 antibody with enhanced antitumor activity against multiple myeloma. Blood. 2022;139(8):1160-1176. [Content Brief]
[3]. Kapoor P, et al. An open-label, first-in-human, single agent, dose escalation study for the evaluation of safety and efficacy of SAR442085 in patients with relapsed or refractory multiple myeloma. Eur J Haematol. 2024;113(5):593-605. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)